IPO Timeline
Broker Results (T-2)
2020-09-24
Some brokers release in afternoon
Grey Market (T-1)
2020-09-25
Afternoon
HKEX Allotment (T-1)
2020-09-25
Evening
Registrar Allotment (T-1)
2020-09-25
Evening
Listing Day (T)
2020-09-28
First day of trading
Company Overview
| Stock Name | 再鼎医药 |
|---|---|
| Stock Code | 09688 |
| Company Full Name | 再鼎医药 |
| Industry | 醫療保健 |
| Principal Activities | 主要從事生物制藥業務，專注於腫瘤、抗感染及自體免疫性疾病療法。 |
| Listing Date | 2020-09-28 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市浦東新區哈雷路899號B幢 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.zailaboratory.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 562.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 504,676,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 610.0 |
|---|---|
| First Day Open | HK$ 613.5 |
| First Day Change | 8.54% |
| First Day Volume | 1075520.0 |
| First Day Turnover | 648951000.0 |
Use of Proceeds
| Use of Proceeds | 1、約46.2%預期將分配至我們的核心產品； 2、約11.8%預期將為進行中及計劃臨床試驗以及管線中其他候選藥物（尤其是晚期候選藥物）的準備中注冊備案撥資； 3、約25.0%預期將用于探索新的全球授權及合作機會并引進具有臨床驗證的潛在全球同類最佳/同類首創資產； 4、約7.0%預期將用于持續投資及擴大我們的內部研發產品管線以及在全球招聘及培訓高端人才； 5、約10.0%預期為營運資金及其他一般企業用途撥資。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
J.P. Morgan Securities (Far East) Limited CE AAB026
高盛（亚洲）有限责任公司 CE ACC536
花旗环球金融亚洲有限公司 CE AAA137
Overall Coordinators (4)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
高盛（亚洲）有限责任公司 CE ACC536
花旗环球金融亚洲有限公司 CE AAA137
富瑞金融集团香港有限公司 CE ATS546
Joint Bookrunners (8)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
高盛（亚洲）有限责任公司 CE ACC536
花旗环球金融亚洲有限公司 CE AAA137
富瑞金融集团香港有限公司 CE ATS546
Merrill Lynch (Asia Pacific) Limited CE AAC198
Credit Suisse (Hong Kong) Limited CE AAO017
中国国际金融香港证券有限公司 CE AEN894
海通国际证券有限公司 CE AAF806
Joint Lead Managers (8)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
高盛（亚洲）有限责任公司 CE ACC536
花旗环球金融亚洲有限公司 CE AAA137
富瑞金融集团香港有限公司 CE ATS546
Merrill Lynch (Asia Pacific) Limited CE AAC198
Credit Suisse (Hong Kong) Limited CE AAO017
中国国际金融香港证券有限公司 CE AEN894
海通国际证券有限公司 CE AAF806
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | 杜瑩 |
|---|---|
| Company Secretary | F.Ty Edmondson |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | FMR LLC(8.67%);Invesco Advisers, Inc.(8.34%);Baillie Gifford & Co.(6.03%) |
|---|
IPO Timeline
